BIOHAVEN PHARMACEUTICAL HOLDING CO LTD
NYSE: BHVN (Biohaven Ltd.)
Last update: 7 hours ago9.86
0.12 (1.23%)
| Previous Close | 9.74 |
| Open | 9.59 |
| Volume | 1,948,040 |
| Avg. Volume (3M) | 2,127,654 |
| Market Cap | 1,484,531,328 |
| Price / Book | 27.82 |
| 52 Weeks Range | |
| Earnings Date | 4 May 2026 |
| Diluted EPS (TTM) | -9.25 |
| Total Debt/Equity (MRQ) | 13.68% |
| Current Ratio (MRQ) | 2.33 |
| Operating Cash Flow (TTM) | -644.94 M |
| Levered Free Cash Flow (TTM) | -394.10 M |
| Return on Assets (TTM) | -129.99% |
| Return on Equity (TTM) | -316.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Biohaven Ltd. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | 2.50 |
|
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 11.96% |
| % Held by Institutions | 90.75% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Suvretta Capital Management, Llc | 31 Dec 2025 | 10,286,937 |
| Stifel Financial Corp | 31 Dec 2025 | 9,939,856 |
| Infinitum Asset Management, Llc | 31 Dec 2025 | 6,250,000 |
| Tcg Crossover Management, Llc | 31 Dec 2025 | 4,631,317 |
| Knoll Capital Management, Llc | 31 Dec 2025 | 2,328,602 |
| Bnp Paribas Financial Markets | 31 Dec 2025 | 2,093,816 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 30.00 (TD Cowen, 204.26%) | Buy |
| Median | 23.00 (133.27%) | |
| Low | 10.00 (HC Wainwright & Co., 1.42%) | Hold |
| Average | 21.00 (112.98%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 10.58 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| TD Cowen | 11 Mar 2026 | 30.00 (204.26%) | Buy | 10.46 |
| HC Wainwright & Co. | 04 Mar 2026 | 10.00 (1.42%) | Hold | 10.61 |
| RBC Capital | 03 Mar 2026 | 23.00 (133.27%) | Buy | 10.67 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |